Abiopharma

🔍 Scanlon Jennifer F. (Executive)

Company: UL Solutions Inc. (ULS)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 14,265 shares of Class A Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: false | shares_owned_after: 186,128.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,320 shares of Class A Common Stock at $84.57 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: false | shares_owned_after: 179,808.00 | transaction_form_type: 4
• Acquired 60,084 shares of Class A Common Stock at $84.57 per share (Direct)
  Date: 2026-04-01 | Code: A | equity_swap_involved: false | shares_owned_after: 239,892.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 26,618 shares of Class A Common Stock at $84.57 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: false | shares_owned_after: 213,274.00 | transaction_form_type: 4
• Sold 4,923 shares of Class A Common Stock at $84.9768 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: false | shares_owned_after: 208,351.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 7,577 shares of Class A Common Stock at $85.8394 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: false | shares_owned_after: 200,774.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-04-01 | Code: H | nature_of_ownership: By Family Trust | shares_owned_after: 89,285.00
• Sold 14,265 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: false | shares_owned_after: 28,534.00 | transaction_form_type: 4 | Footnotes: F1, F6, F6, F7
• Acquired 36,455 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: A | equity_swap_involved: false | shares_owned_after: 36,455.00 | transaction_form_type: 4 | Footnotes: F1, F8, F8

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• F2: The Class A Common Stock was issued to the Reporting Person upon settlement of performance cash awards granted under the Issuer's Pre-IPO Long Term Incentive Plan as a result of the achievement of certain performance criteria not related to the passage of time or stock price.
• F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
• F4: This transaction was executed in multiple trades at prices ranging from $84.44 to $85.43, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: This transaction was executed in multiple trades at prices ranging from $85.44 to $86.39, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The restricted stock units vest in three equal installments on the first, second and third anniversaries of April 1, 2025.
• F7: Includes restricted stock units and all dividend equivalent rights that have accrued on such restricted stock units to date.
• F8: The restricted stock units vest in three equal installments on the first, second and third anniversaries of April 1, 2026.